ATHENA Network


Thu May 12th 10:00am to 11:00am PDT


Olivier Harismendy


The Athena Breast Health Network is a research and care collaboration across the five UC Medical Centers and Sanford Health. In response to the controversy on breast cancer screening guidelines, the network started the WISDOM (Women Informed to Screen Depending On Measures of risk) study to prospectively evaluate a risk-based screening strategy. This strategy incorporates the latest risk assessment model along with co-morbidities, breast density and genetic risk factors. In particular, the DNA of more than 100,000 women will be sequenced at 9 breast cancer risk genes and 76 susceptibiity SNPs. I will describe the study, its goals, rational and participating sites, as well the infrastructure deployed to share the genetic results within the ATHENA Network using the iDASH HIPAA compliant cloud and the Application Programmable Interface from the Global Alliance for Genomic and Health. Progress and Limitations will be discussed. 


Dr. Harismendy graduated with an M.S. in Process Engineering from ENSTA-ParisTech (France) and a joint M.S. in Microbiology from the Pasteur Institute and Paris 7 University. He obtained his Ph.D. in Microbiology from the same university, studying RNA polymerase III transcriptional regulation in yeast using ChIP-chip at Dr Sentenac’s laboratory (CEA-Saclay, France). He then joined Dr. Edelman’s Department of Neurobiology at The Scripps Research Institute (La Jolla, CA), where he developed ChIP-Seq approaches to study Neuron Restrictive Silencing Factor DNA binding in mouse developing brains.

Under the mentorship of Dr. Kelly Frazer, Dr. Harismendy went on to develop applications of high-throughput sequencing for translational research: evaluating methods for targeted sequencing, exploring the role of regulatory variants in common diseases, and detecting and studying the role of somatic mutations in cancer. He joined the UC San Diego Moores Cancer Center in 2009 where he is currently leading the Oncogenomics laboratory. His current research focuses on the development of assays and computational approaches to study tumor heterogeneity predict drug response and understand the contribution of gene regulatory elements in cancer etiology and progression. Strong of his experience in the molecular analysis of clinical samples and the interpretation of the data for cancer care, Dr. Harismendy participates in the molecular tumor board and the protocol monitoring and review committee to review and advise on the design and execution of molecularly guided clinical trials.



Must use web and audio.
Please include name and company when joining meeting.
Web: (Access Code: 2201876)
Audio: 1-866-740-1260 (Access Code: 2201876)
Click here to test your computer's compatibility before the meeting.


IMPORTANT NOTICE: This ReadyTalk service includes a feature that allows audio and any documents and other materials exchanged or viewed during the session to be recorded. By joining this session, you automatically consent to such recordings. If you do not consent to the recording, discuss your concerns with the meeting host prior to the start of the recording or do not join the session. Please note that any such recordings may be subject to discovery in the event of litigation.